Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Bioventix

Healthcare GB BVXP

1650.0GBX
-10.0(0.60%)

Last update at 2026-06-04T11:52:00Z

Day Range

1650.001700.00
LowHigh

52 Week Range

1251.472801.53
LowHigh

Fundamentals

  • Previous Close 1660.00
  • Market Cap94.05M
  • Volume1979
  • P/E Ratio12.86
  • Dividend Yield8.00%
  • EBITDA9.84M
  • Revenue TTM12.54M
  • Revenue Per Share TTM2.40
  • Gross Profit TTM 11.59M
  • Diluted EPS TTM1.40

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax 10.10M 10.57M 10.13M 9.28M 8.12M
Minority interest - - - - -
Net income 7.58M 8.10M 8.37M 7.67M 6.73M
Selling general administrative 2.05M 1.99M 1.77M 1.61M 1.51M
Selling and marketing expenses - 1.02M - - -
Gross profit 11.92M 12.68M 11.99M 11.01M 10.11M
Reconciled depreciation 0.09M 0.11M 0.13M 0.14M 0.14M
Ebit 10.07M 10.63M 10.13M 9.28M 8.38M
Ebitda 10.17M 10.74M 10.26M 9.42M 8.52M
Depreciation and amortization 0.09M 0.11M 0.13M 0.14M 0.14M
Non operating income net other - - - - -
Operating income 9.90M 10.60M 10.03M 9.27M 8.09M
Other operating expenses 3.21M 3.02M 2.75M 2.54M 2.55M
Interest expense - - 0.00000M 0.00030M 0.26M
Tax provision 2.51M 2.51M 1.76M 1.60M 1.39M
Interest income 0.19M 0.20M 0.10M 0.00480M 0.03M
Net interest income 0.19M 0.20M 0.10M 0.00450M 0.03M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 2.51M 2.48M 1.76M 1.60M 1.39M
Total revenue 13.12M 13.61M 12.82M 11.72M 10.93M
Total operating expenses 2.01M 2.10M 1.92M 1.83M 1.73M
Cost of revenue 1.20M 0.93M 0.83M 0.71M 0.82M
Total other income expense net 0.19M 0.02M 0.10M 0.00450M -0.26342M
Discontinued operations - - - - -
Net income from continuing ops 7.58M 8.10M 8.37M 7.67M 6.73M
Net income applicable to common shares - - - 7.67M 6.73M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 12.86M 13.73M 13.28M 13.12M 12.91M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.02M 0.00249M - 5.22M 4.63M
Total liab 1.31M 1.73M 1.22M 1.30M 1.09M
Total stockholder equity 11.55M 12.00M 12.06M 11.82M 11.82M
Deferred long term liab - - - - -
Other current liab 0.36M 0.38M 1.12M 1.09M 1.01M
Common stock 0.26M 0.26M 0.26M 0.26M 0.26M
Capital stock 0.26M 0.26M 0.26M 0.26M 0.26M
Retained earnings 9.75M 10.27M 10.33M 10.23M 10.23M
Other liab - - - 0.04M 0.08M
Good will - - - - -
Other assets - - - - -
Cash 5.08M 6.00M 5.72M 6.13M 6.49M
Cash and equivalents - - - - -
Total current liabilities 1.31M 1.73M 1.20M 1.25M 1.01M
Current deferred revenue - - - - -
Net debt -5.07930M -5.99895M -5.71582M -6.12665M -6.49498M
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity 1.54M 1.47M 1.47M -10.48745M -10.48661M
Property plant equipment - - - 0.69M 0.84M
Total current assets 12.03M 12.83M 12.10M 11.81M 11.45M
Long term investments - - - - -
Net tangible assets - - - 11.82M 11.82M
Short term investments - - - - -
Net receivables 6.24M 6.21M 1.17M 0.76M 4.63M
Long term debt - - - - -
Inventory 0.69M 0.62M 0.57M 0.46M 0.33M
Accounts payable 0.08M 0.17M 0.08M 1.25M 1.01M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00123M 0.00123M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.43M 0.61M -1.30441M -1.45376M
Deferred long term asset charges - - - - -
Non current assets total 0.83M 0.90M 1.19M 1.30M 1.45M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments 0.17M 0.19M 0.09M -0.00695M -0.22920M
Change to liabilities - - - 0.08M 0.06M
Total cashflows from investing activities 0.17M 0.19M - -0.00695M -0.22920M
Net borrowings - - - - -
Total cash from financing activities -8.12461M -8.24706M -8.30370M -7.91849M -7.68959M
Change to operating activities - - - - -
Net income 7.58M 8.10M 8.37M 7.67M 6.73M
Change in cash -0.91966M 0.28M -0.41083M -0.36834M -1.58148M
Begin period cash flow 6.00M 5.72M 6.13M 6.49M 8.08M
End period cash flow 5.08M 6.00M 5.72M 6.13M 6.49M
Total cash from operating activities 7.03M 8.34M 7.80M 7.56M 6.34M
Issuance of capital stock 0.07M 0.00000M 0.14M 0.00000M 0.02M
Depreciation 0.09M 0.11M 0.13M 0.14M 0.14M
Other cashflows from investing activities 0.19M 0.20M - 0.00480M 0.03M
Dividends paid 8.19M 8.25M 8.44M 7.92M 7.71M
Change to inventory -0.07406M -0.04998M -0.10355M -0.12936M -0.08704M
Change to account receivables -0.03411M -0.39467M - -0.59875M -0.97660M
Sale purchase of stock - - - - 0.02M
Other cashflows from financing activities - -0.01591M 0.09M -0.00030M -0.22920M
Change to netincome - - - 0.39M 0.47M
Capital expenditures 0.02M 0.02M 0.01M 0.01M 0.26M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.20630M -0.36163M -0.78271M -0.65176M -1.00412M
Stock based compensation 0.09M 0.09M 0.17M 0.24M 0.26M
Other non cash items -0.52841M 0.50M -0.10109M -0.00450M -0.03063M
Free cash flow 7.01M 8.33M 7.79M 7.55M 6.08M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BVXP
Bioventix		 -10.0 0.60% 1650.00 12.86 11.39 7.50 7.57 6.24 7.96
GNS
Genus PLC		 38.00 1.70% 2274.00 36.08 26.18 2.53 3.46 2.92 15.38
ONT
Oxford Nanopore Technologies Ltd		 5.50 4.09% 140.00 - - 4.71 2.50 4.23 -8.8899
OXB
Oxford BioMedica PLC		 28.00 4.90% 600.00 - 208.33 4.05 7.60 4.42 308.96
AVCT
Avacta Group PLC		 - -% 70.00 - - 2849.46 1929.84 2525.51 -12.0368

Reports Covered

Stock Research & News

View All

Profile

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment. The company also provides contract SMAs services; and industrial and environmental biomonitoring platform, which reduces the time between sampling and results. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.

Bioventix

7 Romans Business Park, Farnham, United Kingdom, GU9 7SX

Key Executives

Name Title Year Born
Mr. Peter John Harrison MA CEO & Director 1958
Mr. Bruce Edward Heath Hiscock CFO & Director 1958

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.